Price T Rowe Associates Inc Biomea Fusion, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 19,352 shares of BMEA stock, worth $54,959. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,352
Previous 18,137
6.7%
Holding current value
$54,959
Previous $184,000
58.7%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding BMEA
# of Institutions
126Shares Held
17.5MCall Options Held
1.8MPut Options Held
1.08M-
Cormorant Asset Management, LP Boston, MA3.57MShares$10.1 Million1.09% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$6.66 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.45MShares$4.12 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.4MShares$3.98 Million0.0% of portfolio
-
Aisling Capital Management LP New York, NY799KShares$2.27 Million1.14% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $83.2M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...